• Molecular NamePropiverine
  • SynonymNA
  • Weight367.489
  • Drugbank_IDN/A
  • ACS_NO54556-98-8
  • Show 2D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)4.97
  • pkaN/A
  • LogD (pH=7, predicted)2.97
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-3.49
  • LogSw (predicted, AB/LogsW2.0)0.01
  • Sw (mg/ml) (predicted, ACD/Labs)0.02
  • No.of HBond Donors0
  • No.of HBond Acceptors4
  • No.of Rotatable Bonds8
  • TPSA38.77
  • StatusN/A
  • AdministrationN/A
  • PharmacologyAn anticholinergic drug used for the treatment of urinary urgency, frequency and urge incontinence, all symptoms of overactive bladder syndrome.
  • Absorption_value84.0
  • Absorption (description)The drug is rapidly absorbed from the gastrointestinal tract
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein binding90.0
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmWidely distributed and undergoes nearly complete biotransformation by N-oxidation, hydroxylation, and dealkylation. Its main metabolite is propiverine N-oxide (M5), which is appropriate for pharmacokinetic studies in humans. It also has several other active metabolites.
  • Half life20.1 h
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityN/A
  • LD50 (rat)N/A
  • LD50 (mouse)N/A